Skip to content
value.today

Genomenon, Inc.

Total raised
$34 M
4 rounds on record
Latest round
$6 M
Jul 2026
First round on record
May 2020
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genomenon, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2026$6 MNo. 4$2 to $10 million

Genomenon, Inc.: Raise no. 4, Jul 2026

Investors in this round

30 investors had bought by the notice of Jul 30, 2026: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $10 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Groark · Executive Officer
  • Mark Kiel · Executive Officer, Director
  • Michael Klein · Executive Officer, Director
  • Sam Globus · Executive Officer
  • David Gregorka · Director
  • Michael Gross · Director
  • Patricia Glaza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Groark, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 30, 2026. Read the notice at the SEC.

equitySEC
May 2024$5 MNo. 3$2 to $10 million

Genomenon, Inc.: Raise no. 3, May 2024

Investors in this round

30 investors had bought by the notice of May 16, 2024: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Kiel · Executive Officer, Director
  • Michael Klein · Executive Officer, Director
  • Sam Globus · Executive Officer
  • Sean Kearney · Executive Officer
  • David Gregorka · Director
  • Michael Gross · Director
  • Patricia Glaza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean Kearney, Chief Financial Officer. Source: SEC Form D, newest notice filed May 16, 2024. Read the notice at the SEC.

equitySEC
Feb 2022$20 MNo. 2$10 to $50 million

Genomenon, Inc.: Raise no. 2, Feb 2022

Investors in this round

23 investors had bought by the notice of Mar 10, 2022: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Kiel · Executive Officer, Director
  • Michael Klein · Executive Officer, Director
  • David Gregorka · Director
  • Michael Gross · Director
  • Patricia Glaza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael T. Klein, Ceo. Source: SEC Form D, newest notice filed Mar 10, 2022. Read the notice at the SEC.

equitySEC
May 2020$3 MNo. 1$2 to $10 million

Genomenon, Inc.: Raise no. 1, May 2020

Investors in this round

36 investors had bought by the notice of May 21, 2020: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Kiel · Executive Officer, Director
  • Michael Klein · Executive Officer, Director
  • Steve Schwartz · Executive Officer
  • Charles Moret · Director
  • David Gregorka · Director
  • Patricia Glaza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael T. Klein, Ceo. Source: SEC Form D, newest notice filed May 21, 2020. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genomenon, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2026).

    SEC Form D · Jul 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2026

That is all the official record says: Genomenon, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Genomenon, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 36 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genomenon, Inc.
NameRoleNamed in
Brian GroarkExecutive officerJul 2026
Mark KielExecutive officerJul 2026
Michael KleinExecutive officerJul 2026
Sam GlobusExecutive officerJul 2026
Sean KearneyExecutive officerMay 2024
Steve SchwartzExecutive officerMay 2020
David GregorkaDirectorJul 2026
Mark KielDirectorJul 2026
Michael GrossDirectorJul 2026
Michael KleinDirectorJul 2026
Patricia GlazaDirectorJul 2026
Charles MoretDirectorMay 2020